The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|February 14, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-01-2017
- Volume 12
- Issue 3
Quotient Clinical Expands US Operations
Author(s)Pharmaceutical Technology Editors
Quotient Clinical’s addition of CDMO QS Pharma increases the company’s footprint in the US an adds high potency molecule capability.
Advertisement
Quotient Clinical announced on Feb. 14, 2017 the acquisition of QS Pharma, a contract development and manufacturing organization based near Philadelphia, from Charles River Laboratories International, Inc. The acquisition increases Quotient’s presence in the US and, will enable the company to replicate its Translational Pharmaceutics platform in America, according to a press statement. On Feb. 6, 2017, Quotient announced the acquisition of SeaView Research, a Florida-based clinical pharmacology business.
Founded in 2002, QS Pharma specializes in the formulation development and manufacturing of small-molecule drug products and supports customer programs through all stages of development and commercialization, including work with high potency molecules.
Quotient’s Translational Pharmaceutics platform integrates clinical testing with formulation development and real-time GMP manufacturing; more than 100 pharmaceutical and biotech companies have chosen Translational Pharmaceutics to accelerate the development of their products, the company reports.
Source:
Articles in this issue
over 9 years ago
Viewpoint: No Clear Path for Pharma or Outsourcingover 9 years ago
Standards Set Excipient GMPs, But Collaboration is Neededover 9 years ago
Monitoring Supply Chain Risk on a Limited Budgetover 9 years ago
Evaluating E&L Studies for Single-Use Systemsover 9 years ago
PfizerCentreOne Expands Fill/Finish Services in Michiganover 9 years ago
Metrohm USA Announces Winner of Young Chemist Awardover 9 years ago
Novasep Opens New Bioconjugation Unit in FranceAdvertisement
Related to this article
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
5